Ivan Efremov
About Ivan Efremov
Ivan Efremov serves as the VP and Head of Medicinal Chemistry at Fulcrum Therapeutics, where he has worked since 2021. He has extensive experience in drug discovery and a strong background in organic synthesis, with over 50 publications and patents in medicinal chemistry.
Current Role at Fulcrum Therapeutics
Ivan Efremov serves as the Vice President and Head of Medicinal Chemistry at Fulcrum Therapeutics, a position he has held since 2021. His work is based in Cambridge, MA, where he leads efforts in medicinal chemistry. Efremov's role involves overseeing the development of innovative therapeutic strategies and managing a team focused on drug discovery.
Previous Positions at Fulcrum Therapeutics
Before becoming VP, Efremov held several positions at Fulcrum Therapeutics. He was the Senior Director and Head of Medicinal Chemistry from 2020 to 2021, and prior to that, he served as Associate Director of Chemistry from 2017 to 2019. He also worked as Director of Chemistry for a year from 2019 to 2020, contributing to the company's drug discovery initiatives.
Experience at Pfizer
Efremov has extensive experience at Pfizer, where he worked for over a decade in various roles. He began as a Research Scientist from 2001 to 2003, then progressed to Senior Research Scientist from 2003 to 2006, and Principal Scientist from 2006 to 2009. He later served as Senior Principal Scientist from 2009 to 2017, focusing on medicinal chemistry and contributing to multiple projects.
Educational Background and Expertise
Efremov earned his Ph.D. in Synthetic Organic Chemistry from The Ohio State University, where he studied from 1996 to 2001. His expertise includes fragment-based drug discovery, organic synthesis, data analytics, multi-parameter optimization, and cheminformatics. He has also published over 50 papers and holds patents in the field of medicinal chemistry.
Contributions to Drug Development
Throughout his career, Efremov has contributed to the development of several active clinical assets, including tavapadon, brepocitinib, and FTX-6058. His work has focused on advancing therapeutic candidates through various stages of drug discovery and development.